Señales en vivo de ASLN | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients...

Stats
Volumen de hoy	292 541
Volumen promedio	1.26M
Capitalización de mercado	7.87M
EPS	$-0.780 ( 2024-05-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.160
ATR14	$0.00900 (1.96%)

Volumen Correlación

Largo: -0.14 (neutral)

Corto: 0.47 (neutral)

Signal:(56.888) Neutral

ASLAN Pharmaceuticals Correlación

10 Correlaciones Más Positivas
TYRA	0.946
RCEL	0.946
SHIP	0.943
ASUR	0.943
XLRN	0.942
OPRA	0.94
AMPH	0.939
RDNT	0.934
FLMN	0.934
LFMDP	0.933

10 Correlaciones Más Negativas
GOODN	-0.944
WISH	-0.943
TBIO	-0.935
TREE	-0.934
UPLD	-0.931
MICS	-0.929
GMVD	-0.927
AVGR	-0.925
BAND	-0.925
GOODO	-0.924

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ASLAN Pharmaceuticals Correlación - Moneda/Commodity

-0.07
( neutral )

0.48
( neutral )

0.00
( neutral )

-0.08
( neutral )

ASLAN Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$12.00M
Beneficio Bruto:	$11.65M (97.10 %)
EPS:	$-2.69

FY	2023
Ingresos:	$12.00M
Beneficio Bruto:	$11.65M (97.10 %)
EPS:	$-2.69

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-331 752 (0.00 %)
EPS:	$-3.68

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.815

Financial Reports:

No articles found.

ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.